{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-25-000009","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2025-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.575949+00:00","generated_at":"2026-05-23T07:44:56.800097+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead Q1 revenue flat at $6.7B; GAAP EPS $1.04 vs -$3.34; cuts GAAP EPS guidance","bullets":["Total revenue $6.7B unchanged YoY; product sales ex-Veklury up 4% to $6.3B.","GAAP diluted EPS $1.04 vs $(3.34) in Q1 2024; non-GAAP diluted EPS $1.81 vs $(1.32).","Biktarvy sales $3.1B (+7% YoY); HIV product sales up 6% to $4.6B.","Full-year GAAP diluted EPS guidance cut to $5.65-$6.05 from $5.95-$6.35; product sales unchanged.","Cash $7.9B; operating cash flow $1.8B; $1.0B dividends, $730M buyback in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-25-000009","json":"https://secwatch.observer/filing/0000882095-25-000009.json","markdown":"https://secwatch.observer/filing/0000882095-25-000009.md","text":"https://secwatch.observer/filing/0000882095-25-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/0000882095-25-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000009/gild-20250424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T07:44:56.800097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}